Ionis Pharmaceuticals Inc (IONS) company profile
Close on Nov 18, 2026Market cap $4.55BP/E –Yield –
About Ionis Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and delivers RNA-targeted medicines to treat serious and life-threatening human diseases. Its core therapeutic focus areas include neurology, cardiometabolic disorders, and select areas of high unmet patient need. The company's marketed product portfolio features therapies such as Tryngolza, Dawnzera, Wainua, Spinraza, Qalsody, Tegsedi, and Waylivra. These treatments serve patients suffering from severe conditions, including familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis polyneuropathy, spinal muscular atrophy, and amyotrophic lateral sclerosis. In addition to commercializing products independently in select markets, the company partners with global pharmaceutical firms to co-develop and distribute its therapies worldwide.
The company's commercialized products and clinical operations reach patients across multiple international markets, with regulatory approvals and active distribution agreements spanning the United States, the European Union, Canada, China, Japan, the United Kingdom, and Brazil. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Ionis Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ionis Pharmaceuticals Inc
- Founded
- 1989
- Headquarters
- Carlsbad, CA
- Address
- 2855 Gazelle Court 92010
- Phone
- (760) 931-9200
- Website
- www.ionispharma.com
- Employees
- 1,402, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- California
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- IONS
- Exchange
- Nasdaq
- IPO date
- May 17, 1991
- Shares outstanding
- 166M, Jul 23, 2026
- Public float
- $5.28B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 874015
- CUSIP
- 462222100
- ISIN
- US4622221004
- FIGI
- BBG000JH6683
- Share class FIGI
- BBG001SB7RD1
- LEI
- 549300SI4ZGLG0BLUZ92
- EIN
- 33-0336973
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brett P. Monia | Chief Executive Officer, Director | 242,760 |
| Eric Swayze | EVP Research | 22,149 |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 17,811 |
| Brian Birchler | EVP, Corp and Development Ops | 102,883 |
| C. Frank Bennett | EVP, Chief Scientific Officer | 75,128 |
| Patrick R. O'Neil | EVP CLO & General Counsel | 59,205 |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 22,096 |
| Joseph Baroldi | EVP, Chief Business Officer | 53,191 |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 77,114 |
| Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 23,713 |
| Elizabeth L. Hougen | EVP, Finance & CFO | 82,660 |
| Richard S. Geary | EVP, Chief Development Officer | 59,657 |
| Michael R. Hayden | Director | 81,298 |
| Joan E. Herman | Director | 51,306 |
| Spencer R. Berthelsen | Director | 161,303 |
| Ludwig Hantson | Director | – |
| Peter N. Reikes | Director | 14,222 |
| Allene M. Diaz | Director | 13,922 |
| Joseph Klein Iii | Director | 11,214 |
| Michael J. Yang | Director | 7,940 |
| Joseph Loscalzo | Director | 54,111 |
| B. Lynne Parshall | Director | 52,878 |
| Joseph H. Wender | Director | 52,035 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.35M | $42.61M | $3.49M | $140 | $125 |
| FY2024 | $15.40M | -$2.70M | $4.07M | $58 | $118 |
| FY2023 | $12.50M | $14.22M | $2.70M | $84 | $119 |
| FY2022 | $7.26M | $9.54M | $2.80M | $63 | $114 |
| FY2021 | $13.31M | -$2.60M | $3.83M | $50 | $126 |
| FY2020 | $10.96M | $3.44M | $5.45M | $94 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Brett P. Monia Chief Executive Officer | $1.05M | $2.40M | $8.44M | $1.44M | $18.01K | $13.35M | -13% |
| Elizabeth L. Hougen EVP, Finance and Chief Financial Officer | $729.75K | $831.92K | $2.30M | $516.81K | $43.01K | $4.42M | -13% |
| Richard S. Geary EVP, Chief Development Officer | $622.07K | $661.89K | $1.63M | $366.77K | $47.83K | $3.33M | -4% |
| Brian Birchler EVP, Corporate and Development Operations | $580.15K | $617.28K | $1.63M | $366.77K | $48.01K | $3.25M | -3% |
| Eric Swayze EVP, Research | $589.01K | $626.71K | $1.63M | $366.77K | $18.01K | $3.23M | -6% |
| Patrick R. O’Neil EVP, Chief Legal Officer and General Counsel | $611.79K | $581.20K | $1.63M | $366.77K | $18.01K | $3.21M | -6% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 19, 2026, we employed 1,402 people, the vast majority of whom reside in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 24, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 28, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 13, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 14, 2020 | Tender offer | Third-party tender offer for the company's shares |
| Dec 18, 2015 | Name change | Name changed from ISIS PHARMACEUTICALS INC to Ionis Pharmaceuticals Inc |
| Jan 12, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 28, 2007 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 10, 2006 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
See a number that looks wrong?